Allogene Therapeutics, Inc.
Biotechnology, Health Care, Therapeutics · 1,000 employees
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to creat
Funding history
- Funding Round — $411.8M — Apr 2018
Recent signals
- Apr 13, 2026: SEC 8-K (8.01): On April 13, 2026, Allogene Therapeutics, Inc. announced an interim futility analysis from its pivotal Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) for the treatment of large B-cell lymphoma (LBCL). This trial is significant as it is the first randomized study aimed at assessing whether minimal residual disease (MRD)-guided interventions can effectively eliminate residual disease in high-risk patients before relapse. The study utilizes Natera’s investigational CLARITY™ MRD assay to identify patients eligible for treatment. The outcomes reported in this analysis may influence future strategies for managing LBCL and improving patient survival rates, marking a crucial development in cancer treatment methodologies.
- Feb 26, 2025: Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics for Joint Development Activities Outside the US
- Oct 16, 2023: Allogene Therapeutics Appoints Geoffrey Parker as Chief
- Apr 19, 2018: Raised $411.8M
See plans & pricing → Track Allogene Therapeutics, Inc.’s funding, hiring, and signals — with verified contacts — on Fundz.